Stock Events

Stock Events

Ernexa Therapeutics 

$0.069900
121
+$0.02+53.63% 19:17 Today

Statistics

Day High
0.0502
Day Low
0.0402
52W High
0.0502
52W Low
0.0402
Volume
7,069
Avg. Volume
-
Mkt Cap
81,526.68
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-6.95
-4.84
-2.72
-0.61
Expected EPS
-3.84
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-14.1MNet Income

Analyst Ratings

30.00Average Price Target
The highest estimate is 30.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ERNAW. It's not an investment recommendation.
Realty Income
24
O
Schwab US Dividend Equity
24
SCHD
JPMorgan Equity Premium Income
23
JEPI
NVIDIA
22
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leader in the development of gene-based therapies, directly competing with Eterna's focus on mRNA and gene editing technologies.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing space, making it a direct competitor to Eterna Therapeutics in the development of gene therapy solutions.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing in the same space as Eterna Therapeutics.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor in the gene therapy market alongside Eterna Therapeutics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with Eterna's focus on mRNA therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the RNA space with Eterna.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, which can be seen as complementary or competitive to gene therapies offered by Eterna.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals, with its focus on treating genetic diseases, competes in the broader market for genetic therapies that Eterna is also targeting.

About

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Show more...
CEO
Sanjeev Luther
Employees
5
Country
United States
ISIN
US1140821182

Listings

NYSE
US
BTX
XNAS
US
ERNA
XNAS
US
ERNAW
BOATS
BOATS
ERNA.BOATS

0 Comments

Share your thoughts

FAQ

What is Ernexa Therapeutics stock price today?▼
The current price of ERNAW is $0.07 USD — it has increased by +53.63% in the past 24 hours. Watch Ernexa Therapeutics stock price performance more closely on the chart.
What is Ernexa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ernexa Therapeutics stocks are traded under the ticker ERNAW.
What is Ernexa Therapeutics market cap?▼
Today Ernexa Therapeutics has the market capitalization of 81,526.68
When is the next Ernexa Therapeutics earnings date?▼
Ernexa Therapeutics is going to release the next earnings report on November 11, 2026.
What were Ernexa Therapeutics earnings last quarter?▼
ERNAW earnings for the last quarter are -3.3 USD per share, whereas the estimation was -3.3 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ernexa Therapeutics revenue for the last year?▼
Ernexa Therapeutics revenue for the last year amounts to 0 USD.
What is Ernexa Therapeutics net income for the last year?▼
ERNAW net income for the last year is -14.1M USD.
How many employees does Ernexa Therapeutics have?▼
As of September 04, 2026, the company has 5 employees.
In which sector is Ernexa Therapeutics located?▼
Ernexa Therapeutics operates in the Health & Wellness sector.
When did Ernexa Therapeutics complete a stock split?▼
The last stock split for Ernexa Therapeutics was on May 04, 2026 with a ratio of 1:25.
Where is Ernexa Therapeutics headquartered?▼
Ernexa Therapeutics is headquartered in CAMBRIDGE, United States.